Mathews Sujata E, Srivastava Dinesh, Balayadav Raj, Sharma Anjali
Department of Medicine, Dr. Ram Manohar, Lohia Hospital and Post Graduate Institute of Medical Research, New Delhi, India.
J Lab Physicians. 2013 Jan;5(1):34-7. doi: 10.4103/0974-2727.115929.
This work was carried out to study the hematologic profile of human immunodeficiency virus (HIV)-positive patients and its association with the clinicoimmunologic stage of the disease.
A total of 187 patients with HIV, whether symptomatic or asymptomatic, diagnosed by enzyme-linked immunosorbent assay (ELISA) method according to the National AIDS Control Organization (NACO) guidelines were included in this study. Patients in the study population were divided into two groups: (1) Group A (antiretroviral therapy (ART) included patients receiving ART [ART-Y]) and (2) Group B included treatment naïve patients (ART-N). The patients were tested for hemoglobin (Hb), total red blood cells (RBC) count, RBC indices, reticulocyte count, packed cell volume (PCV), total lymphocyte counts(TLC), differential leukocyte counts (DLC), platelet count, and erythrocyte sedimentation rate (ESR). Cut-off values were determined as Hb < 10 g/dl, platelet count < 1.5 lakh/cumm, and TLC < 4,000/cumm. The group or categorical data were tested for statistical significance using Chi-square test and Z-test. The difference was reported as significant if P < 0.05.
(1) Anemia (predominantly normocytic normochromic) was prevalent in 40.1%, with slightly higher prevalence in those not receiving ART. It occurred with high frequency in patients with immunological (42.05%) and clinical acquired immunodeficiency disease syndrome (AIDS) (70.58%) compared with those who had an asymptomatic HIV infection with CD4 > 200/μl (28.57%). Patients on zidovudine (AZT) therapy had 34.6% anemia with increased mean corpuscular volume (MCV). (2) Thrombocytopenia was seen in 3.74% patients (higher percentage in untreated patients). (3) Leucopenia was observed in 5.88% in ART-Y (Group A) and 8.14% in ART-N (Group B) patients. (4) Pancytopenia was found in 1.6% patients.
开展此项研究以探讨人类免疫缺陷病毒(HIV)阳性患者的血液学特征及其与疾病临床免疫阶段的关联。
本研究纳入了187例经酶联免疫吸附测定(ELISA)法诊断为HIV感染的患者,无论其有无症状,诊断均依据国家艾滋病控制组织(NACO)的指南。研究人群中的患者分为两组:(1)A组(抗逆转录病毒治疗(ART)组,即接受ART的患者[ART-Y])和(2)B组,包括未接受过治疗的患者(ART-N)。对患者进行血红蛋白(Hb)、总红细胞(RBC)计数、RBC指数、网织红细胞计数、血细胞比容(PCV)、总淋巴细胞计数(TLC)、白细胞分类计数(DLC)、血小板计数及红细胞沉降率(ESR)检测。将临界值确定为Hb < 10 g/dl、血小板计数 < 15万/立方毫米及TLC < 4000/立方毫米。使用卡方检验和Z检验对组间数据或分类数据进行统计学显著性检验。若P < 0.05,则差异具有统计学显著性。
(1)贫血(主要为正细胞正色素性贫血)患病率为40.1%,未接受ART的患者患病率略高。与CD4>200/μl的无症状HIV感染患者(28.57%)相比,免疫功能受损患者(42.05%)和临床获得性免疫缺陷综合征(AIDS)患者(70.58%)中贫血的发生率更高。接受齐多夫定(AZT)治疗的患者贫血发生率为34.6%,平均红细胞体积(MCV)增加。(2)3.74%的患者出现血小板减少(未治疗患者中的比例更高)。(3)接受ART的患者(A组)中5.88%出现白细胞减少,未接受ART的患者(B组)中8.14%出现白细胞减少。(4)1.6%的患者出现全血细胞减少。